Pharnext (FR:ALPHA) has released an update.
Pharnext SCA, a biopharmaceutical company focused on developing therapies for untreatable neurodegenerative diseases, reported the total number of shares and voting rights in their share capital as of May 31, 2024. The company also detailed the number of shares issued from conversions and stock option exercises over the recent months. Investors are cautioned about potential share price volatility and capital dilution due to the company’s dilutive financing operations, particularly with Global Tech Opportunities 13 and a trust arrangement.
For further insights into FR:ALPHA stock, check out TipRanks’ Stock Analysis page.
